Skip to content
CIZ Cizzle Biotechnology Holdings Plc LSE
1.89 GBp -0.63% -0.01
OPEN 1.89
PREV CLOSE 1.90
DAY RANGE 1.89 - 1.89
VOLUME 56350
AVG. VOLUME 3.1M
52 WEEK RANGE 2.80 - 1.42
Interactive Brokers Logotype

Buy CIZ ETF now with Interactive Brokers – the most advanced investment platform

Valuations metrics

Market capitalization 7.5M
Enterprise value 6.2M
Trailing pe 1.7000002
Peg ratio 0.025500003
Price to book mrq 949.99994
Enterprise to ebitda -32.714645502646

Financials

Fiscal year ends 2023-12-31
Most recent quarter 2023-12-31
Return on assets ttm -0.31717
Return on equity ttm -1.57812
Income statement
Net income to common ttm -2697000
Diluted eps ttm -0.01
Balance sheet
Total cash mrq 816K
Total cash per share mrq 0.002
Current ratio mrq 7.155
Book value per share mrq 0.002
Cash flow
Operating cash flow ttm -550000
Levered free cash flow ttm -156125

ETF statistics

Shares outstanding 396.4M
Float shares 291.6M
Avg 10 volume 3.2M
Avg 90 volume 1.5M
Percent held by insiders 0.43651

ETF price summary

Fifty two week low 1.42
Fifty two week high 2.8
Fifty two week change -37.705
Beta 0.372
Day 50 ma 1.778
Day 200 ma 1.8023

Dividends and splits

Dividend frequency Unknown

VictoryShares Developed Enhanced Volatility Wtd ETF

No description available at this time

Sign Up

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

Already have an account?

Services

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.